1. HBW Insight

FTC's Prevagen Complaint Revived: Court Says 'Deceptive' Ad Allegation Plausible

 
• By Eileen Francis

District court erred in dismissing FTC complaint that Prevagen marketer Quincy Biosciences used deceptive representations in ads, Second Circuit says in long-awaited order. FTC and New York attorney general, along with advocacy group TINA, criticize Quincy's post hoc data analyses finding "false positives."

A federal appeals court did not rebuke a standard the Federal Trade Commission imposes for substantiating health claims, as the dietary supplement industry hoped, in a ruling on a complaint alleging misleading memory claims for the Prevagen cognitive health supplement.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Business